Ameliorative effects of GW1929, a nonthiazolidinedione PPARγ agonist, on inflammation and apoptosis in focal cerebral ischemic-reperfusion injury

Current Neurovascular Research

Volumn 8, Issue 3, 2011, Pages 236-245

  Kaundal, Ravinder K ^a   Sharma, Shyam S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Cerebral ischemia; GW1929; Inflammation; Neuroprotection; Pioglitazone; Ppar gamma agonists; Stroke

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; DRUG MECHANISM; INFLAMMATION; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

EID: 80051528861     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/156720211796558078     Document Type: Article

References (52)

1. Bakhai A. The burden of coronary, cerebrovascular and peripheral arterial disease. Pharmacoeconomics 2004; 22: 11-8. (Pubitemid 40066089)
2. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2009; 40(5): e331-9.
3. Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg 2009; 111(6): 483-95.
4. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003; 34(1): 40-6.
5. Chu K, Lee ST, Koo JS, et al. Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res 2006; 1093(1): 208-18. (Pubitemid 43946402)
6. Collino M, Aragno M, Mastrocola R, et al. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2006; 530(1-2): 70-80. (Pubitemid 43037126)
7. Culman J, Zhao Y, Gohlke P, Herdegen T. PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 2007; 28(5): 244-9. (Pubitemid 46661003)
8. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371(9624): 1612-23. (Pubitemid 351626845)
9. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 2007; 87(1): 179-97. (Pubitemid 46860315)
10. Eliasson MJ, Huang Z, Ferrante RJ, et al. Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neural damage. J Neurosci 1999; 19(14): 5910-8. (Pubitemid 29327926)
11. Gamboa J, Blankenship DA, Niemi JP, et al. Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion. Neuroscience 2010; 170(3): 846-57.
12. Giaginis C, Giagini A, Theocharis S. Peroxisome proliferatoractivated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis. Pharmacol Res 2009; 60(3): 160-9.
13. Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med 2010; 48(9): 1121-32.
14. Glatz T, Stock I, Nguyen-Ngoc M, et al. Peroxisome-proliferatoractivated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. J Hypertens 2010; 28(7): 1488-97.
15. Holt JA, Consler TG, Williams SP, et al. Helix 1/8 interactions influence the activity of nuclear receptor ligand-binding domains. Mol Endocrinol 2003; 17(9): 1704-14. (Pubitemid 37072288)
16. Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol 2006; 66(3): 232-45. (Pubitemid 44279808)
17. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 2010; 87(5): 779-89.
18. Kabra DG, Thiyagarajan M, Kaul CL, Sharma SS. Neuroprotective effect of 4-amino-1,8-napthalimide, a poly(ADP ribose) polymerase inhibitor in middle cerebral artery occlusion-induced focal cerebral ischemia in rat. Brain Res Bull 2004; 62(5): 425-33. (Pubitemid 38198329)
19. Kaundal RK, Iyer S, Kumar A, Sharma SS. Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils. J Pharmacol Sci 2009; 109(3): 361-7.
20. Kaundal RK, Shah KK, Sharma SS. Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. Life Sci 2006; 79(24): 2293-302. (Pubitemid 44767638)
21. Kaundal RK, Sharma SS. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect 2010; 23(4): 241-56.
22. Kaundal RK, Sharma SS. GW1929: A nonthiazolidinedione PPARgamma agonist, ameliorates neurological damage in global cerebral ischemic-reperfusion injury through reduction in inflammation and DNA fragmentation. Behav Brain Res 2011; 216(2): 606-12.
23. Kim KY, Cho HS, Lee SH, Ahn JH, Cheon HG. Neuroprotective effects of KR-62980, a new PPARgamma agonist, against chemical ischemia-reperfusion in SK-N-SH cells. Brain Res 2011; 1372: 103-14.
24. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005; 51(2): 85-94. (Pubitemid 40040538)
25. Kumar P, Kaundal RK, More S, Sharma SS. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behav Brain Res 2009; 197(2): 398-403.
26. Lee SR, Kim HY, Hong JS, Baek WK, Park JW. PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia. Biochem Biophys Res Commun 2009; 380(1): 17-21.
27. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20(1): 84-91. (Pubitemid 19040218)
28. Marcet-Palacios M, Graham K, Cass C, Befus AD, Mayers I, Radomski MW. Nitric oxide and cyclic GMP increase the expression of matrix metalloproteinase-9 in vascular smooth muscle. J Pharmacol Exp Ther 2003; 307(1): 429-36. (Pubitemid 37151936)
29. Mayers I, Hurst T, Radomski A, et al. Increased matrix metalloproteinase activity after canine cardiopulmonary bypass is suppressed by a nitric oxide scavenger. J Thorac Cardiovasc Surg 2003; 125(3): 661-8. (Pubitemid 36373914)
30. Nitatori T, Sato N, Waguri S, et al. Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis. J Neurosci 1995; 15(2): 1001-11.
31. Patzer A, Zhao Y, Stock I, Gohlke P, Herdegen T, Culman J. Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. Eur J Neurosci 2008; 28(9): 1786-94.
32. Pei L, Zhang Y, Chu X, et al. Peroxisome proliferator-activated receptor gamma promotes neuroprotection by modulating cyclic D1 expression after focal cerebral ischemia. Can J Physiol Pharmacol 2010; 88(7): 716-23.
33. Pereira MP, Hurtado O, Cardenas A, et al. The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J Neuropathol Exp Neurol 2005; 64(9): 797-805. (Pubitemid 41285813)
34. Pereira MP, Hurtado O, Cardenas A, et al. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 2006; 26(2): 218-29. (Pubitemid 43151578)
35. Pettigrew LC, Kindy MS, Scheff S, et al. Focal cerebral ischemia in the TNFalpha-transgenic rat. J Neuroinflammation 2008; 5: 47-66.
36. Planas AM, Sole S, Justicia C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 2001; 8(5): 834-46. (Pubitemid 33055599)
37. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006; 37(6): 1399-406. (Pubitemid 44305716)
38. Sharma R, Kaundal RK, Sharma SS. Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs. Pulm Pharmacol Ther 2009; 22(3): 183-9.
39. Sharma SS, Dhar A, Kaundal RK. FeTPPS protects against global cerebral ischemic-reperfusion injury in gerbils. Pharmacol Res 2007; 55(4): 335-42. (Pubitemid 46518162)
40. Sharma SS, Kaundal RK. Neuroprotective effects of 6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxylic acid (Trolox), an antioxidant in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Neurol Res 2007; 29(3): 304-9. (Pubitemid 46802369)
41. STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30(12): 2752-8.
42. Sun M, Zhao Y, Gu Y, Xu C. Neuroprotective actions of aminoguanidine involve reduced the activation of calpain and caspase-3 in a rat model of stroke. Neurochem Int 2010; 56(4): 634-41.
43. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005; 130(3): 685-96. (Pubitemid 39601441)
44. Tuttolomondo A, Di Raimondo D, di Sciacca R, Pinto A, Licata G. Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des 2008; 14(33): 3574-89.
45. Van Wagoner NJ, Benveniste EN. Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol 1999; 100(1-2): 124-39. (Pubitemid 30038246)
46. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007; 184(1-2): 53-68. (Pubitemid 46365991)
47. Wang X, Yue TL, Young PR, Barone FC, Feuerstein GZ. Expression of interleukin-6, c-fos, and zif268 mRNAs in rat ischemic cortex. J Cereb Blood Flow Metab 1995; 15(1): 166-71.
48. Weinstein JR, Koerner IP, Moller T. Microglia in ischemic brain injury. Future Neurol 2010; 5(2): 227-46.
49. Wu JS, Cheung WM, Tsai YS, et al. Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 2009; 119(8): 1124-34.
50. Zhao Y, Patzer A, Gohlke P, Herdegen T, Culman J. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci 2005; 22(1): 278-82. (Pubitemid 41059994)
51. Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J. Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 2006; 20(8): 1162-75. (Pubitemid 44943912)
52. Zuhayra M, Zhao Y, von Forstner C, et al. Activation of cerebral peroxisome proliferator - activated receptors gamma (PPARgamma) reduces neuronal damage in the substantia nigra after transient focal cerebral ischaemia in the rat. Neuropathol Appl Neurobiol 2011 doi: 10.1111/j.1365-2990.2011.01169.